Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
Allogeneic Peripheral Blood Stem Cell Transplantation With Minimally Myelosuppressive Regimen of Pentostatin and Low-dose Total-body Irradiation
Sponsor: Astex Pharmaceuticals, Inc.
This PHASE2 trial investigates Acute Lymphocytic Leukemia and Acute Myelogenous Leukemia and is currently completed. Astex Pharmaceuticals, Inc. leads this study, which shows 10 recorded versions since 2000 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Nov 2023 [monthly]
Completed PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Dec 2018 — Feb 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Completed PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Mar 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astex Pharmaceuticals, Inc.
- University of Nebraska
For direct contact, visit the study record on ClinicalTrials.gov .